Alnylam announced third-quarter global net product revenues of $1.292 billion, representing 52% year-over-year growth, driven largely by its TTR franchise.
In a separate update, the company reported positive Phase 1b data for ALN-HTT02 in Huntington’s disease, with durable target lowering and plans to advance toward a pivotal study in 2027.
